News

The deal combines Daiichi Sankyo’s ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab (formerly PankoMab-GEX), building on a previous 2017 option agreement. Under the terms of the

The approval is for the intravenous use of the Azedra injection in patients whose adrenal gland tumors are unresectable and have spread beyond the original tumor site and

Since 2015, scientists from Lilly and Dana-Farber have been working together on pre-clinical and clinical studies, molecular analyses of patient samples and the design and conduct of clinical

The company has announced the positive top-line safety and efficacy results from the MAP US study, which showed superiority of RHB-104 over placebo. RHB-104 is a proprietary and

In addition, Marken has begun their unique hybrid service for shipments into Russia for drug storage and distribution and from Russia for biologic sample shipments.  Together, these new

The recommendation is based on the progression-free survival (PFS) and overall survival (OS) primary endpoints of the Phase III PACIFIC trial, and post-hoc subgroup analyses by PD-L1 expression

It is the fourth Sandoz biosimilar approved in Europe in past 18 months, and seventh in total. Hyrimoz is an inhibitor of tumor necrosis factor (TNF), a protein

Clinically relevant levels were reached after the first injection of PERSERIS without use of a loading dose or any supplemental oral risperidone.1 “Treatment adherence is a major challenge

The pharmaceutical secondary packaging company said that patients can handle their medication intake more easily owing to intelligent, interactive pharmaceutical packaging with integrated electronics. Faller said that its